Key result
Causal Lp(a) role supports universal one-time adult screening for ASCVD risk stratification.
Answers are grounded in this paper and cite their sources.
This review highlights the causal role of lipoprotein(a) in ASCVD and supports current recommendations to measure it at least once in all adults for risk stratification.
The fact that lipoprotein(a) levels should be regarded as a causal residual risk factor in the atherosclerotic cardiovascular diseases (ASCVD) is now a no-brainer. This review article aims to summarize the latest evidence supporting the causal role of lipoprotein(a) in ASCVD and the potential strategies to reduce the lipoprotein(a) burden until clinical trial results are available. Epidemiological and genetic data demonstrate the causal link between lipoprotein(a) and increased ASCVD risk. That being said, a specific question comes to mind: "must we wait for outcome trials in order to take action?". Given that lipoprotein(a) levels predict incident ASCVD in both primary and secondary prevention contexts, with a linear risk gradient across its distribution, measuring lipoprotein(a) can unequivocally help identify patients who may later benefit from specific lipoprotein(a)-lowering therapies. This understanding has led various National Societies to recommend dosing lipoprotein(a) in high-risk individuals and to support the recommendation of measuring lipoprotein(a) levels at least once in every adult for risk stratification.
No takes yet. Share an insight, caveat, or question.
Fichtner et al. (2024) conducted a review in Atherosclerotic cardiovascular diseases (ASCVD). Lipoprotein(a) was evaluated. Lipoprotein(a) is a causal risk factor for atherosclerotic cardiovascular disease, supporting recommendations to measure its levels at least once in every adult for risk stratification.
Synapse has enriched 10 related papers. Consider them for comparative context: